Skip NavigationSkip to Content
Return Return to Search Results

Design and biological activity of novel stealth polymeric lipid nanoparticles for enhanced delivery of hydrophobic photodynamic therapy drugs

  1. Author:
    Viard, Mathias
    Reichard, Henry
    Shapiro, Bruce
    Durrani, Farukh A
    Marko, Aimee J
    Watson, R Michelle
    Pandey, Ravindra K
    Puri, Anu

  2. Author Address

    RNA Structure and Design Section, RNA Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, U.S.A.; Leidos Biomedical Research Inc., Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, U.S.A., Photodynamic Therapy Center, Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY, U.S.A., Photodynamic Therapy Center, Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY, U.S.A.. Electronic address: Ravindra.Pandey@RoswellPark.org., RNA Structure and Design Section, RNA Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, U.S.A.. Electronic address: puria@mail.nih.gov.,
    1. Year: 2018
    2. Date: Oct
    3. Epub Date: 2018 07 27
  2. Journal: Nanomedicine : nanotechnology, biology, and medicine
    1. 14
    2. 7
    3. Pages: 2295-2305
  4. Type of Article: Article
  5. ISSN: 1549-9634
  1. Abstract:

    Advances in in vivo stability and preferential tumor uptake of cancer nanomedicine are warranted for effective chemotherapy. Here, we describe a novel nanoformulation using an unconventional polymeric tubule-forming phospholipid, DC8,9PC. We report that DC8,9PC transitions to stable vesicles (LNPs) in the presence of PEGylated lipid (DSPE-PEG2000); the resulting DC8,9PC:DSPE-PEG2000 LNPs efficiently included a hydrophobic PDT drug, HPPH. Remarkably, these LNPs incorporated unusually high DSPE-PEG2000 concentrations; LNP10-HPPH and LNP20-HPPH (10 & 20 mol% PEGylated lipid, respectively) exhibited >90% serum stability at 37°C. Increased PEGylation in the LNPs correlated with enhanced tumor accumulation in intravenously injected HT29 tumor mouse xenographs. Colon-26 bearing BALB/c mice, intravenously injected with LNP20-HPPH showed superior PDT efficacy and animal survival (no tumor recurrence up to 100 days) as compared to a formulation currently used in clinical trials. Taken together, we present a simple stealth binary lipid nanosystem with enhanced efficiency of tumor accumulation and superior therapeutic efficacy. Copyright © 2018. Published by Elsevier Inc.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.nano.2018.07.006
  3. PMID: 30059754
  4. View record in Web of Science®
  5. WOS: 000446496900029
  6. PII : S1549-9634(18)30496-9

Library Notes

  1. Fiscal Year: FY2017-2018
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel